title: Carbapenem-resistant Acinetobacter baumannii: epidemiology, surveillance and management.
abstract: Carbapenem-resistant Acinetobacter baumannii pose a significant threat to hospitalized patients, as therapeutic options are scarse. Alarmingly, rates of carbapenem-resistance in A. baumannii are on the rise and are slowly becoming a routine phenotype for this organism. This review focuses on infection control strategies for identification and control of A. baumannii, as well the available therapeutic options.
authors.affiliation: Department of Pharmacy, Sinai-Grace Hospital, Detroit Medical Center, 6071 W Outer Dr Detroit, MI 48235, USA. jpogue@dmc.org
authors.forename: Jason M
authors.initials: JM
authors.lastname: Pogue
authors.forename: Tal
authors.initials: T
authors.lastname: Mann
authors.forename: Katie E
authors.initials: KE
authors.lastname: Barber
authors.forename: Keith S
authors.initials: KS
authors.lastname: Kaye
mesh_terms: D000151:Acinetobacter Infections / Q000188:drug therapy* / Q000453:epidemiology* / Q000382:microbiology; D040981:Acinetobacter baumannii / Q000145:classification / Q000187:drug effects / Q000235:genetics*; D000617:Aminoglycosides / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D015780:Carbapenems / Q000627:therapeutic use; D003091:Colistin / Q000627:therapeutic use; D019468:Disease Management; D004196:Disease Outbreaks; D062665:Epidemiological Monitoring; D006801:Humans; D008911:Minocycline / Q000031:analogs & derivatives / Q000627:therapeutic use; D000078304:Tigecycline; D018440:beta-Lactam Resistance / Q000187:drug effects / Q000235:genetics*; D001618:beta-Lactamases / Q000145:classification / Q000235:genetics
chemical_list: D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D015780:Carbapenems; D000078304:Tigecycline; D001618:beta-Lactamases; D008911:Minocycline; D003091:Colistin